PDCD1 and alkaline phosphatase measurement: Immune checkpoint inhibitors targeting the PD-1 are currently in clinical trials in sepsis, to determine their efficacy in reversing T cell anergy and exhaustion (230) and findings here may have some relevance to synonymous phenomena in AP.